Experts discuss pressing issues related to checkpoint inhibitor use, including irAEs and use in autoimmune disease and organ transplant.
This activity is intended for nurses, nurse practitioners, and other healthcare professionals who treat cancer patients with immune checkpoint inhibitors.
The goal of this activity is to increase understanding of the issues surrounding immune checkpoint inhibitors (ICIs), including the risk for immune-related adverse events (irAEs) and optimal patient/caregiver communication.
Approximate Time to Complete: 30 minutes
Credit Available: Nov. 25, 2019 - Nov. 25, 2020
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Have increased knowledge regarding the Factors, such as medications and a patient's medical history, that may influence the efficacy of ICIs in patients with cancer
- Have greater competence related to optimizing communication between the cancer care team and the patient/caregiver related to irAEs, including reporting and identifying toxicities
- Have greater competence related to applying best nursing practices in the management of irAEs